Age-dependent maturation of toll-like receptor-mediated cytokine responses in gambian infants

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Burl, Sarah ^a,b   Townend, John ^a   Njie Jobe, Jainaba ^a   Cox, Momodou ^a   Adetifa, Uche J ^a   Touray, Ebrima ^a   Philbin, Victoria J ^c   Mancuso, Christy ^c   Kampmann, Beate ^a,b   Whittle, Hilton ^a   Jaye, Assan ^a   Flanagan, Katie L ^a   Levy, Ofer ^c  

^a Medical Research Council (UK) The Gambia   (Gambia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA;

AGE; ARTICLE; CHILD DEVELOPMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; GAMBIAN; HUMAN; HUMAN CELL; INDIGENOUS PEOPLE; INFANT; INNATE IMMUNITY; NEWBORN; PROTEIN BLOOD LEVEL; TH1 CELL; TH2 CELL; UMBILICAL CORD BLOOD; CROSS-SECTIONAL STUDY; DNA MICROARRAY; GAMBIA; PHYSIOLOGY; SECRETION;

CROSS-SECTIONAL STUDIES; CYTOKINES; GAMBIA; HUMANS; IMMUNITY, INNATE; INFANT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TOLL-LIKE RECEPTORS;

EID: 79954578695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018185     Document Type: Article

References (63)

1. UNICEF (2009) Reducing Child Mortality: Millennium Development Goals. UNICEF.
2. Demirjian A, Levy O, (2008) Safety and efficacy of neonatal vaccination. Eur J Immunol.
3. van den Biggelaar AH, Richmond PC, Pomat WS, Phuanukoonnon S, Nadal-Sims MA, et al. (2009) Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: a randomized controlled trial in Papua New Guinea. Vaccine 27: 1340-1347.
4. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, et al. (2009) Neonatal Innate TLR-Mediated Responses Are Distinct from Those of Adults. J Immunol 183: 7150-7160.
5. Siegrist CA, (2001) Neonatal and early life vaccinology. Vaccine 19: 3331-3346.
6. Upham JW, Rate A, Rowe J, Kusel M, Sly PD, et al. (2006) Dendritic cell immaturity during infancy restricts the capacity to express vaccine-specific T-cell memory. Infect Immun 74: 1106-1112.
7. Philbin VJ, Levy O, (2009) Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 65: 98R-105R.
8. Prabhudas M, Adkins B, Gans H, King C, Levy O, et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 12: 189-194.
9. Marodi L, (2006) Innate cellular immune responses in newborns. Clin Immunol 118: 137-144.
10. Willems F, Vollstedt S, Suter M, (2009) Phenotype and function of neonatal DC. Eur J Immunol 39: 26-35.
11. Yan SR, Qing G, Byers DM, Stadnyk AW, Al-Hertani W, et al. (2004) Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Infect Immun 72: 1223-1229.
12. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, et al. (1999) Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol 163: 2249-2255.
13. Belderbos M, Levy O, Bont L, (2009) Neonatal innate immunity in allergy development. Curr Opin Pediatr 21: 762-769.
14. Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, et al. (2000) Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 204: 64-74.
15. Wu JJ, Huang DB, Tyring SK, (2004) Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 64: 79-83.
16. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA, (2005) Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 174: 7676-7683.
17. Pulendran B, Li S, Nakaya HI, (2010) Systems vaccinology. Immunity 33: 516-529.
18. Katsenelson N, Kanswal S, Puig M, Mostowski H, Verthelyi D, et al. (2007) Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol 37: 1785-1795.
19. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, et al. (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183: 6186-6197.
20. Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, et al. (2009) Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 44: 33-40.
21. Boland G, Beran J, Lievens M, Sasadeusz J, Dentico P, et al. (2004) Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23: 316-320.
22. Nicholls EF, Madera L, Hancock RE, (2010) Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann N Y Acad Sci Early viewing online.
23. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543-1551.
24. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521-2532.
25. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, et al. (2008) Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359: 2533-2544.
26. Coffman RL, Sher A, Seder RA, (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
27. Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, et al. (2006) Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 116: 916-928.
28. Davila S, Hibberd ML, Hari Dass R, Wong HE, Sahiratmadja E, et al. (2008) Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet 4: e1000218.
29. Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, et al. (2003) Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun 71: 4238-4249.
30. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, et al. (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 68: 6883-6890.
31. Latz E, Franko J, Golenbock DT, Schreiber JR, (2004) Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 172: 2431-2438.
32. Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, et al. (2010) Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine in press.
33. Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, et al. (2007) Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 204: 2407-2422.
34. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, et al. (2004) Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 173: 4627-4634.
35. Goriely S, Goldman M, (2007) From tolerance to autoimmunity: is there a risk in early life vaccination? J Comp Pathol 137 (Suppl 1): S57-61.
36. De Wit D, Tonon S, Olislagers V, Goriely S, Boutriaux M, et al. (2003) Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J Autoimmun 21: 277-281.
37. Nguyen M, Leuridan E, Zhang T, De Wit D, Willems F, et al. (2010) Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS One 5: e10407.
38. Schultz C, Rott C, Temming P, Schlenke P, Moller JC, et al. (2002) Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res 51: 317-322.
39. Belderbos ME, van Bleek GM, Levy O, Blanken MO, Houben ML, et al. (2009) Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: Low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin Immunol.
40. Angelone DF, Wessels MR, Coughlin M, Suter EE, Valentini P, et al. (2006) Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. Pediatr Res 60: 205-209.
41. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, et al. (2006) The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 177: 1956-1966.
42. Vanden Eijnden S, Goriely S, De Wit D, Goldman M, Willems F, (2006) Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. Eur J Immunol 36: 21-26.
43. Levy O, Suter EE, Miller RL, Wessels MR, (2006) Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 108: 1284-1290.
44. Vosters O, Lombard C, Andre F, Sana G, Sokal EM, et al. (2010) The interferon-alpha and interleukin-10 responses in neonates differ from adults, and their production remains partial throughout the first 18 months of life. Clin Exp Immunol.
45. Yerkovich ST, Wikstrom ME, Suriyaarachchi D, Prescott SL, Upham JW, et al. (2007) Postnatal development of monocyte cytokine responses to bacterial lipopolysaccharide. Pediatr Res 62: 547-552.
46. Lalor MK, Ben-Smith A, Gorak-Stolinska P, Weir RE, Floyd S, et al. (2009) Population Differences in Immune Responses to Bacille Calmette-Guerin Vaccination in Infancy. J Infect Dis.
47. van den Biggelaar AH, Prescott SL, Roponen M, Nadal-Sims MA, Devitt CJ, et al. (2009) Neonatal innate cytokine responses to BCG controlling T-cell development vary between populations. J Allergy Clin Immunol.
48. Jacobson NG, Szabo SJ, Guler ML, Gorham JD, Murphy KM, (1995) Regulation of interleukin-12 signal transduction during T helper phenotype development. Res Immunol 146: 446-456.
49. Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, et al. (1995) Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 181: 1755-1762.
50. Burl S, Adetifa UJ, Cox M, Touray E, Ota MO, et al. (2010) Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 185: 2620-2628.
51. Madura Larsen J, Benn CS, Fillie Y, van der Kleij D, Aaby P, et al. (2007) BCG stimulated dendritic cells induce an interleukin-10 producing T-cell population with no T helper 1 or T helper 2 bias in vitro. Immunology 121: 276-282.
52. Levy O, (2007) Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 7: 379-390.
53. Kimura A, Kishimoto T IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40: 1830-1835.
54. Peck A, Mellins ED, (2009) Precarious balance: Th17 cells in host defense. Infect Immun 78: 32-38.
55. Dorschner RA, Lin KH, Murakami M, Gallo RL, (2003) Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res 53: 566-572.
56. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
57. Strachan DP, (1989) Hay fever, hygiene, and household size. Bmj 299: 1259-1260.
58. Rook GA, Hamelmann E, Brunet LR, (2007) Mycobacteria and allergies. Immunobiology 212: 461-473.
59. Casella CR, Mitchell TC, (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65: 3231-3240.
60. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, et al. (1998) The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16: 495-521.
61. Robinson DS, O'Garra A, (2002) Further checkpoints in Th1 development. Immunity 16: 755-758.
62. Goriely S, Vincart B, Stordeur P, Vekemans J, Willems F, et al. (2001) Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol 166: 2141-2146.
63. Pulendran B, (2009) Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 9: 741-747.